Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea
L. Katherine Morrison, BS*,
Alex Harrison, BS*,
Padma Krishnaswamy, MD*,
Radmila Kazanegra, MD*,
Paul Clopton, MS* and
Alan Maisel, MD, FACC*,*
* Division of Cardiology, Veteran’s Affairs Medical Center, and the Department of Medicine, University of California, San Diego, California, USA
View larger version (25K):
[in a new window]
|
Figure 1 B-type natriuretic peptide (BNP) levels of patients diagnosed with congestive heart failure (CHF), baseline left ventricular dysfunction, pulmonary disease, other cardiac disease and other noncardiac, nonpulmonary disease.
|
|
View larger version (29K):
[in a new window]
|
Figure 2 Receiver operating characteristic curve comparing the sensitivity and specificity of B-type natriuretic peptide (BNP) in differentiating congestive heart failure (CHF) from non-CHF in patients presenting with dyspnea. Selected BNP values are indicated in pg/ml. Listed below the figure are accuracies of various cut-points of BNP. AUC = area under curve and is significant, p < 0.001.
|
|
View larger version (27K):
[in a new window]
|
Figure 3 Mean ± SD for B-type natriuretic peptide (BNP) values in patients with various types of pulmonary disease. COPD = chronic obstructive pulmonary disease; TB = tuberculosis.
|
|
View larger version (23K):
[in a new window]
|
Figure 4 B-type natriuretic peptide (BNP) levels in patients with a past history of pulmonary disease but a final diagnosis of acute congestive heart failure (CHF), as well as patients with a past history of CHF but a final diagnosis of acute pulmonary disease. Data are expressed as mean ± SE for BNP values. COPD = chronic obstructive pulmonary disease.
|
|
|
